Abstract

Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): Results of a multicentric Italian observational study.
Alessia D'Alonzo ... Chiara Dellepiane
Journal of Clinical Oncology | VOL. 36
Alessia D'Alonzo, et. al.Alessia D'Alonzo ... Chiara Dellepiane
20 May 2018
Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study
Alessandra Fabi ...
American Journal of Cancer | VOL. 80
Alessandra Fabi, et. al.Alessandra Fabi ...
14 Feb 2020
Abstract OT2-01-01: Trial in Progress: Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy
Stephanie Van De Ven ... Francois Tranquart
American Journal of Cancer | VOL. 83
Stephanie Van De Ven, et. al.Stephanie Van De Ven ... Francois Tranquart
01 Mar 2023
BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel
Lobna R Ezz Elarab ... Manal El Mahdy
The Chinese-German Journal of Clinical Oncology | VOL. 9
Lobna R Ezz Elarab, et. al.Lobna R Ezz Elarab ... Manal El Mahdy
01 Dec 2010
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis
S Martín-Lluesma ... G Coukos
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
S Martín-Lluesma, et. al.S Martín-Lluesma ... G Coukos
23 Jul 2024
Exploiting the tumor microenvironment and tumor mechanobiology for the treatment of cancer cachexia
Kostas A Papavassiliou ... Athanasios G Papavassiliou
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Kostas A Papavassiliou, et. al.Kostas A Papavassiliou ... Athanasios G Papavassiliou
23 Jul 2024
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
N Colombo ... M Jalving
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
N Colombo, et. al.N Colombo ... M Jalving
22 Jul 2024
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
Rodrigo Sánchez-Bayona ... Mafalda Oliveira
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
Rodrigo Sánchez-Bayona, et. al.Rodrigo Sánchez-Bayona ... Mafalda Oliveira
22 Jul 2024
View more papers